Empiric broad-spectrum intravenous antibiotic, preferably a third generation cephalosporin such as cefotaxime, is warranted for suspected or established<unk>  bacterial peritonitis (SBP) to cover the most common isolates including Escherichia coli, Klebsiella pneumoniae, and Streptococcus pneumoniae. Oral ofloxacin may be considered in selected cases. Albumin infusion should be reserved for patients with ascitic fluid PMN counts greater than or equal to 250 cells/mm3 and clinical suspicion of SBP, who also have a serum creatinine >1 mg/dL, blood urea nitrogen >30 mg/dL, or total bilirubin >4 mg/dL. The use of non-selective beta blockers in cirrhotic patients with SBP should be discouraged since it is associated with an increased risk for hemodynamic compromise, prolonged hospitalization, hepatorenal syndrome, and acute kidney injury.
Spontaneous bacterial peritonitis medical therapy
Secondary peritonitis medical therapy
Ascending cholangitis medical therapy
Acute cholecystitis medical therapy
Peritonitis medical therapy
Chronic cholecystitis medical therapy
Spontaneous bacterial peritonitis surgery
Mesenteric ischemia medical therapy